| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/08/2006 | EP1599212A4 Combination therapy for the treatment of immunoinflammatory disorders |
| 02/08/2006 | EP1467762B1 Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis |
| 02/08/2006 | EP1309328A4 Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
| 02/08/2006 | EP1088104B1 Methods for treating a neurological disease by determining bche genotype |
| 02/08/2006 | EP0969855B1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/08/2006 | EP0812356B1 Prostate-specific membrane antigen and uses thereof |
| 02/08/2006 | CN1732146A Cycloalkyl inhibitors of potassium channel function |
| 02/08/2006 | CN1732000A Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 02/08/2006 | CN1731998A Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 02/08/2006 | CN1731996A Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination |
| 02/08/2006 | CN1731989A A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 02/08/2006 | CN1731988A Sustained release pharmaceutical composition |
| 02/08/2006 | CN1730099A Immune isolated cell medicine, its preparing process and its application in killing tumours |
| 02/08/2006 | CN1240836C Transforming growth factor alpha HI |
| 02/08/2006 | CN1240388C Selective estrogen receptor modulator in combination with dehydroepiandrosterone or its derivative |
| 02/08/2006 | CN1240387C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 02/08/2006 | CN1240384C Transdermal administration of huperzine |
| 02/08/2006 | CN1240382C Medicine combinations using pyridoindolone derivatives and anticancer agent as base |
| 02/07/2006 | US6995241 Acute Neuronal Induced Calcium-Binding Protein (ANIC-BP-1B) polypeptides and polynucleotides; diagnostic assays; neuroprotectants; agonists; antagonists; stroke , Parkinson's disease, Alzheimer disease, multiple sclerosis and spinal cord injuries |
| 02/07/2006 | US6995181 hyterocyclylaminomethyl- or aminocarbonyl-substituted 9,10-ethanoanthracenes or their aza derivatives; treating obesity, diabetes, inflammatory and immune disorders |
| 02/07/2006 | US6995175 Anticancer agents |
| 02/07/2006 | US6995174 for inhibiting proteases |
| 02/07/2006 | US6995169 Synergistic mixture |
| 02/07/2006 | US6995164 Methods of treating tumors |
| 02/07/2006 | US6995159 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)-pyrimidine, 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; for treatment of seizure and eating disorders; reduced side effects |
| 02/07/2006 | US6994993 Nucleotide sequences coding membrane protein for use inthe treatment of epilepsey, arrhythmia, and pain in humans |
| 02/07/2006 | US6994981 Modulators of paraptosis and related methods |
| 02/07/2006 | US6994957 Using nucleic acid |
| 02/07/2006 | US6994869 amino acid source, a carbohydrate source, a lipid source, and a fatty acid delivery agent wherein the fatty acid has a bond hydrolysable in the colon to deliver free fatty acids such as short chain fatty acid acetate without having adverse affect |
| 02/07/2006 | US6994863 Pharmaceutical and cosmetic carrier and composition for topical application |
| 02/07/2006 | US6994848 Lactobacillus paracasei strain GM-080 for treating allergy related diseases |
| 02/07/2006 | US6994843 Delivery of stimulants through an inhalation route |
| 02/07/2006 | CA2360308C Glucocorticoid receptor modulators |
| 02/07/2006 | CA2209848C Pharmaceutical and dietary composition containing sodium, potassium, magnesium and calcium ions and enzyme activators |
| 02/02/2006 | WO2006011915A1 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 02/02/2006 | WO2006011588A1 Medicinal composition containing diabetes remedy |
| 02/02/2006 | WO2006011007A1 Combination anticancer therapy and pharmaceutical compositions therefore |
| 02/02/2006 | WO2005123130A3 Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
| 02/02/2006 | WO2005117532A3 Method for improved breast milk feeding to reduce the risk of allergy |
| 02/02/2006 | WO2005115472A3 Compositions comprising gamma-linolenic acid and iodine for improving breast health in women |
| 02/02/2006 | WO2005107782A3 Use of a modulator of gene expression in the treatment of cancer |
| 02/02/2006 | WO2005105833A3 Novel herpes simplex viruses and uses thereof |
| 02/02/2006 | WO2005105116A3 Inhibition of biogenic sulfide production via biocide and metabolic inhibitor combination |
| 02/02/2006 | WO2005089100A3 Decontamination formulations for disinfection and sterilization |
| 02/02/2006 | WO2005058230A3 Topical use of halosalicylic acid derivatives |
| 02/02/2006 | WO2005056056A3 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 02/02/2006 | WO2005051413A3 Disease associated genes |
| 02/02/2006 | WO2005001038A3 Recombinant anti-cd30 antibodies and uses thereof |
| 02/02/2006 | WO2004093801A3 Pharmaceutical products |
| 02/02/2006 | WO2004012669A3 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 02/02/2006 | WO2002094990A3 Receptors and membrane-associated proteins |
| 02/02/2006 | US20060026700 Tissue specific genes and gene clusters |
| 02/02/2006 | US20060025581 Novel human GABA receptor proteins and polynucleotides encoding the same |
| 02/02/2006 | US20060025576 Multivalent antibodies and uses therefor |
| 02/02/2006 | US20060025573 Reducing the immunogenicity of fusion proteins |
| 02/02/2006 | US20060025469 Methods for decreasing beta amyloid protein |
| 02/02/2006 | US20060025442 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/02/2006 | US20060025426 controlling signal transduction; anticancer agents; angiogenesis inhibitors; vision defects; cardiovascular disorders; antidiabetic agents; antiischemic agents; antiinflamamtory agents |
| 02/02/2006 | US20060025385 L-DOPA amide derivatives and uses thereof |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025342 Administering parathyroid hormone-related protein intermittently at a dosage of at least 500 mu g/day for at least one month,to increase bone mass densityat a rate of at least 1% per month; treating osteoporosis |
| 02/02/2006 | US20060025333 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 02/02/2006 | US20060024795 Interferon-Like molecules and uses thereof |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024728 GM-CSF and/or defensin protein expression regulators in epithelial cells comprising ETS transcription factor or gene encoding the same |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024393 Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases |
| 02/02/2006 | US20060024373 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 02/02/2006 | US20060024336 Ion binding compositions |
| 02/02/2006 | US20060024306 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024265 Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload |
| 02/02/2006 | US20060024238 Compositions and methods using proton pump inhibitors |
| 02/02/2006 | US20060024234 Protein markers for pharmaceuticals and related toxicity |
| 02/02/2006 | CA2587019A1 Combination anticancer therapy and pharmaceutical compositions therefore |
| 02/02/2006 | CA2575683A1 Chn-1/chip-antagonists for the treatment of muscular diseases |
| 02/02/2006 | CA2575518A1 Medicinal composition as immunosuppressant |
| 02/02/2006 | CA2574907A1 Physiologically-active composition based on collagen |
| 02/02/2006 | CA2574627A1 Compositions for treatment of inflammation and pain using a combination of a cox-2 selective inhibitor and a ltb4 receptor antagonist |
| 02/02/2006 | CA2571926A1 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 02/02/2006 | CA2571347A1 Piperazine derivatives for the treatment of female sexual disorders |
| 02/01/2006 | EP1621199A1 Remedies for diseases to be applied to eye |
| 02/01/2006 | EP1621198A2 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists |
| 02/01/2006 | EP1621193A2 Treatment of non-painful bladder disorders using alpha2-delta-subunit calcium channel modulators |
| 02/01/2006 | EP1621188A1 Ultraviolet-shielding type patch |
| 02/01/2006 | EP1621077A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 02/01/2006 | EP1620564A2 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620128A1 Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620124A2 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 02/01/2006 | EP1620107A1 Method of improved diuresis in individuals with impaired renal function |
| 02/01/2006 | EP1620106A1 Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid |
| 02/01/2006 | EP1620104A1 Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use |
| 02/01/2006 | EP1620103A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 02/01/2006 | EP1620083A2 Combination therapies |
| 02/01/2006 | EP1620079A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 02/01/2006 | EP1620078A2 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
| 02/01/2006 | EP1620069A2 Warning and nonirritating lubricant fungicide compositions in the form of a gel |
| 02/01/2006 | EP1620067A1 Cosmetic and/or pharmaceutical preparations |